Literature DB >> 11393778

The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.

N L Fazzalari1, J S Kuliwaba, G J Atkins, M R Forwood, D M Findlay.   

Abstract

The determinants of cancellous bone turnover and trabecular structure are not understood in normal bone or skeletal disease. Bone remodeling is initiated by osteoclastic resorption followed by osteoblastic formation of new bone. Receptor activator of nuclear factor kappaB ligand (RANKL) is a newly described regulator of osteoclast formation and function, the activity of which appears to be a balance between interaction with its receptor RANK and with an antagonist binding protein osteoprotegerin (OPG). Therefore, we have examined the relationship between the expression of RANKL, RANK, and OPG and indices of bone structure and turnover in human cancellous bone from the proximal femur. Bone samples were obtained from individuals with osteoarthritis (OA) at joint replacement surgery and from autopsy controls. Histomorphometric analysis of these samples showed that eroded surface (ES/BS) and osteoid surface (OS/BS) were positively associated in both control (p < 0.001) and OA (p < 0.02), indicating that the processes of bone resorption and bone formation remain coupled in OA, as they are in controls. RANKL, OPG, and RANK messenger RNA (mRNA) were abundant in human cancellous bone, with significant differences between control and OA individuals. In coplotting the molecular and histomorphometric data, strong associations were found between the ratio of RANKL/OPG mRNA and the indices of bone turnover (RANKL/OPG vs. ES/BS: r = 0.93, p < 0.001; RANKL/OPG vs. OS/BS: r = 0.80, p < 0.001). These relationships were not evident in trabecular bone from severe OA, suggesting that bone turnover may be regulated differently in this disease. We propose that the effective concentration of RANKL is related causally to bone turnover.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11393778     DOI: 10.1359/jbmr.2001.16.6.1015

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  32 in total

1.  Osteoblast extracellular Ca2+ -sensing receptor regulates bone development, mineralization, and turnover.

Authors:  Melita M Dvorak-Ewell; Tsui-Hua Chen; Nathan Liang; Caitlin Garvey; Betty Liu; Chialing Tu; Wenhan Chang; Daniel D Bikle; Dolores M Shoback
Journal:  J Bone Miner Res       Date:  2011-12       Impact factor: 6.741

2.  Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.

Authors:  Olafur S Indridason; Leifur Franzson; Gunnar Sigurdsson
Journal:  Osteoporos Int       Date:  2004-07-20       Impact factor: 4.507

Review 3.  Relationship between serum RANKL and RANKL in bone.

Authors:  D M Findlay; G J Atkins
Journal:  Osteoporos Int       Date:  2011-08-18       Impact factor: 4.507

4.  Effects of spinal cord injury on osteoblastogenesis, osteoclastogenesis and gene expression profiling in osteoblasts in young rats.

Authors:  S-D Jiang; L-S Jiang; L-Y Dai
Journal:  Osteoporos Int       Date:  2006-10-12       Impact factor: 4.507

5.  Increased cancellous bone in the femoral neck of patients with coxarthrosis (hip osteoarthritis): a positive remodeling imbalance favoring bone formation.

Authors:  G R Jordan; N Loveridge; J Power; M T Clarke; J Reeve
Journal:  Osteoporos Int       Date:  2003-03-05       Impact factor: 4.507

6.  Triglyceride metabolism in bone tissue is associated with osteoblast and osteoclast differentiation: a gene expression study.

Authors:  Jana Dragojevič; Janja Zupan; Gregor Haring; Simon Herman; Radko Komadina; Janja Marc
Journal:  J Bone Miner Metab       Date:  2013-04-16       Impact factor: 2.626

7.  Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis.

Authors:  Steeve Kwan Tat; Nathalie Amiable; Jean-Pierre Pelletier; Christelle Boileau; Daniel Lajeunesse; Nicolas Duval; Johanne Martel-Pelletier
Journal:  Rheumatology (Oxford)       Date:  2009-09-17       Impact factor: 7.580

8.  Bone marrow stromal cell lines having high potential for osteoclast-supporting activity express PPARgamma1 and show high potential for differentiation into adipocytes.

Authors:  Katsuhisa Takagi; Akira Kudo
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

9.  Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease.

Authors:  Y Y Yuan; P J Kostenuik; M S Ominsky; S Morony; S Adamu; D T Simionescu; D M Basalyga; F J Asuncion; T A Bateman
Journal:  Osteoporos Int       Date:  2007-11-24       Impact factor: 4.507

10.  Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.

Authors:  Kageyama Yasunori; Takahashi Masaaki; Nagafusa Tetsuyuki; Kobayashi Hayato; Nagano Akira
Journal:  Clin Rheumatol       Date:  2008-03-13       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.